J&J's Stelara meets Phase III Crohn's endpoint

The Janssen unit of Johnson & Johnson (NYSE:JNJ) said Stelara ustekinumab met the primary endpoint in the Phase III UNITI-2 study to treat moderate to severe Crohn's disease. Spokesperson Brian Kenney said Janssen is planning global regulatory submissions in the indication this year. The human mAb inhibiting IL-12 and IL-23 is approved in the U.S. and EU to treat plaque psoriasis and psoriatic arthritis. ...